# Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

> **NCT05579977** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 902 (actual)

## Conditions studied

- Diabetes Mellitus
- Obesity

## Interventions

- **DRUG:** PF-07081532
- **OTHER:** Placebo
- **DRUG:** Rybelsus

## Key facts

- **NCT ID:** NCT05579977
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-27
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-09-22
- **Target enrollment:** 902 (ACTUAL)
- **Why stopped:** The decision to terminate clinical development of PF-07081532 is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579977, "Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05579977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*